european organisation for research and treatment of cancer
... efforts of basic research scientists and clinicians from the European continent. The ultimate goal of the EORTC is to improve the standard of cancer treatment in Europe, through the development of new drugs and other innovative approaches, and to test more effective therapeutic strategies, using dru ...
... efforts of basic research scientists and clinicians from the European continent. The ultimate goal of the EORTC is to improve the standard of cancer treatment in Europe, through the development of new drugs and other innovative approaches, and to test more effective therapeutic strategies, using dru ...
Australian Public Assessment Report for Abatacept Proprietary Product Name: Orencia
... lymphocytic inflammation of the thyroid and pancreatic islets were evident. These findings are indicative of an autoimmune response. The sponsor submitted an investigative study to elucidate whether these inflammatory findings were associated with anti abatacept antibody production. At doses below t ...
... lymphocytic inflammation of the thyroid and pancreatic islets were evident. These findings are indicative of an autoimmune response. The sponsor submitted an investigative study to elucidate whether these inflammatory findings were associated with anti abatacept antibody production. At doses below t ...
- eScholarship@UMMS
... performed with older adults (age over 40 years). Little information is available on younger adults (18 to 40 years) who are living with ICDs. Therefore, the purpose of this qualitative descriptive study was to examine the experiences of younger adults (18 to 40 years) living with an ICD. With the in ...
... performed with older adults (age over 40 years). Little information is available on younger adults (18 to 40 years) who are living with ICDs. Therefore, the purpose of this qualitative descriptive study was to examine the experiences of younger adults (18 to 40 years) living with an ICD. With the in ...
Salmeterol + Fluticasone propionate
... At Treatment Week 4, the mean maximal percent fall in FEV1 observed after exercise challenges conducted approximately 8.5 hours post-dose, was significantly less in the combination therapy group when compared to the FP group in the ITT population. No new safety signal was detected. Assessor’s commen ...
... At Treatment Week 4, the mean maximal percent fall in FEV1 observed after exercise challenges conducted approximately 8.5 hours post-dose, was significantly less in the combination therapy group when compared to the FP group in the ITT population. No new safety signal was detected. Assessor’s commen ...
PDF - Undiagnosed Diseases Network International
... programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; ...
... programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; ...
Module 2.5 Clinical Overview
... genome integration is a vital step in retroviral replication, it is an attractive target for HIV therapy. Dolutegravir (DTG, GSK1349572) is an INI owned by ViiV Healthcare, which is working with GlaxoSmithKline (GSK) to develop the asset. Raltegravir (RAL), the first marketed INI, and elvitegravir ( ...
... genome integration is a vital step in retroviral replication, it is an attractive target for HIV therapy. Dolutegravir (DTG, GSK1349572) is an INI owned by ViiV Healthcare, which is working with GlaxoSmithKline (GSK) to develop the asset. Raltegravir (RAL), the first marketed INI, and elvitegravir ( ...
1 ——— CONTRAINDICATIONS ——— Hypersensitivity to the
... In a monkey cardiovascular safety pharmacology model evaluating the combination of excessive doses of TRETTEN® (585 IU/kg, 17 times the expected human dose) in combination with rFVIIa (1000 mcg/kg, 11 times the expected human dose), one of the twelve monkeys died 4 hours after treatment due to throm ...
... In a monkey cardiovascular safety pharmacology model evaluating the combination of excessive doses of TRETTEN® (585 IU/kg, 17 times the expected human dose) in combination with rFVIIa (1000 mcg/kg, 11 times the expected human dose), one of the twelve monkeys died 4 hours after treatment due to throm ...
Boston Scientific Inc. PROMUSâ„¢ Everolimus Eluting Coronary
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
The PROMUS® Everolimus Eluting Coronary Stent System
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
In February 2013, GlaxoSmithKline (GSK)
... unless otherwise stated, were performed at a significance level of alpha=0.05, two-sided. Unless otherwise noted, continuous variables were summarized descriptively using number of subjects (n), mean, standard deviation (SD), median, minimum, and maximum, and categorical variables were summarized de ...
... unless otherwise stated, were performed at a significance level of alpha=0.05, two-sided. Unless otherwise noted, continuous variables were summarized descriptively using number of subjects (n), mean, standard deviation (SD), median, minimum, and maximum, and categorical variables were summarized de ...
Table 3: Brain imaging studies of patients with hypertension, without
... lower in treated HTN vs. untreated HTN. 5. Positive correlations between executive functioning and mean diffusivity and between psychomotor speed and mean Nacetylaspartate/creatine in untreated HTN subjects. 6. No correlations between neuropsychological performance and MRS in treated HTN subjects. ...
... lower in treated HTN vs. untreated HTN. 5. Positive correlations between executive functioning and mean diffusivity and between psychomotor speed and mean Nacetylaspartate/creatine in untreated HTN subjects. 6. No correlations between neuropsychological performance and MRS in treated HTN subjects. ...
- EBioMedicine
... study objectives. Therefore, observer/investigator bias was avoided. Screening tests were applied to only the three high-risk groups and not normal volunteers, as were all comparative analyses; therefore, the exaggeration of the magnitude of association of any risk factor was avoided. No postulation ...
... study objectives. Therefore, observer/investigator bias was avoided. Screening tests were applied to only the three high-risk groups and not normal volunteers, as were all comparative analyses; therefore, the exaggeration of the magnitude of association of any risk factor was avoided. No postulation ...
AusPAR: Eplerenone - Therapeutic Goods Administration
... Overall, the study design and study inclusion and exclusion criteria were appropriate and consistent with the TGA adopted EU guidelines on the clinical investigation of drugs for treatment of cardiac failure, and aimed to recruit a study population of adult patients ≥55 years of age with chronic hea ...
... Overall, the study design and study inclusion and exclusion criteria were appropriate and consistent with the TGA adopted EU guidelines on the clinical investigation of drugs for treatment of cardiac failure, and aimed to recruit a study population of adult patients ≥55 years of age with chronic hea ...
An Evidence-Based Systematic Review of Goji
... Statistically significant evidence of benefit from >2 properly randomized trials (RCTs), OR evidence from one properly conducted RCT AND one properly conducted meta-analysis, OR evidence from multiple RCTs with a clear majority of the properly conducted trials showing statistically significant evide ...
... Statistically significant evidence of benefit from >2 properly randomized trials (RCTs), OR evidence from one properly conducted RCT AND one properly conducted meta-analysis, OR evidence from multiple RCTs with a clear majority of the properly conducted trials showing statistically significant evide ...
50 Years SAKK Active Against Cancer!
... cantons, higher education and private individuals. SAKK with its network can be seen as a successful example where private and public financing go hand in hand. Clinical research survives not merely through the initiative and commitment of individuals, but it relies heavily on the cooperation of exp ...
... cantons, higher education and private individuals. SAKK with its network can be seen as a successful example where private and public financing go hand in hand. Clinical research survives not merely through the initiative and commitment of individuals, but it relies heavily on the cooperation of exp ...
Otezla - Celgene
... The applicant has undertaken a comprehensive clinical development programme covering the essential aspects in relation to this new chemical entity within the Phase I Clinical Pharmacology and Phase2/3 Efficacy and Safety programmes. In addition to standard pharmacokinetics and pharmacodynamics, the ...
... The applicant has undertaken a comprehensive clinical development programme covering the essential aspects in relation to this new chemical entity within the Phase I Clinical Pharmacology and Phase2/3 Efficacy and Safety programmes. In addition to standard pharmacokinetics and pharmacodynamics, the ...
South Australian Cancer Research Strategy
... Yet, the challenge of ‘beating cancer’ lies largely ahead of us and much work still needs to be done. For an increasing proportion of the population cancer is a chronic disease, but unfortunately for some in the South Australian community, cancer is still seen as a death sentence and is evidence of ...
... Yet, the challenge of ‘beating cancer’ lies largely ahead of us and much work still needs to be done. For an increasing proportion of the population cancer is a chronic disease, but unfortunately for some in the South Australian community, cancer is still seen as a death sentence and is evidence of ...
AAPB`s Ethical Principles
... Biofeedback is a physiologically based learning tool to help people recognize how their physiologies are functioning under various circumstances. They can use this information to learn how to control those aspects that are not functioning optimally. With proper training, biofeedback can be used by ...
... Biofeedback is a physiologically based learning tool to help people recognize how their physiologies are functioning under various circumstances. They can use this information to learn how to control those aspects that are not functioning optimally. With proper training, biofeedback can be used by ...
ALBUMIN (HUMAN) 25% SOLUTION, USP
... oncotic activity necessitates careful observation to detect and treat severed blood vessels which may not have bled at the lower blood pressure. Special Populations Pregnant and Nursing Women Animal reproduction studies have not been conducted with ALBUMIN (HUMAN) 25% SOLUTION, USP. It is not known ...
... oncotic activity necessitates careful observation to detect and treat severed blood vessels which may not have bled at the lower blood pressure. Special Populations Pregnant and Nursing Women Animal reproduction studies have not been conducted with ALBUMIN (HUMAN) 25% SOLUTION, USP. It is not known ...
CLINICAL GROUP CLINICAL MONITORING RESEARCH PROGRAM CLINICAL RESEARCH
... recognized that there are numerous barriers to conducting clinical research not only domestically, but particularly in an international setting. Successful completion of our mission directly benefits the mission of NCI, NIAID, and other institutes, and has contributed to improving the overall standa ...
... recognized that there are numerous barriers to conducting clinical research not only domestically, but particularly in an international setting. Successful completion of our mission directly benefits the mission of NCI, NIAID, and other institutes, and has contributed to improving the overall standa ...
Ongoing Clinical Trials Posters II Thursday, February 12, 2015, 6:15
... cumulative ordinal logistic regression adjusted by minimization factors and tPA. A central blinded evaluator adjudicates this score using a video recording. Criteria for missing data imputation on mRS is done by the blinded trial steering committee. Maximum sample size is planned to be 690 patients ...
... cumulative ordinal logistic regression adjusted by minimization factors and tPA. A central blinded evaluator adjudicates this score using a video recording. Criteria for missing data imputation on mRS is done by the blinded trial steering committee. Maximum sample size is planned to be 690 patients ...
Report on the Deliberation Results December 3, 2012 Evaluation
... may be approved and that this result should be reported to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product and its reexamination period should be until September 2 ...
... may be approved and that this result should be reported to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product and its reexamination period should be until September 2 ...
[9] Ifeolu Akinnola, IBP MD/PhD Student
... Background Early-life iron deficiency (ID) compromises the developing hippocampus, driving adult deficits despite iron repletion. The gene expression changes and regulatory mechanisms that drive these lasting deficits are poorly understood. In previous animal studies of ID, concurrent anemia has bee ...
... Background Early-life iron deficiency (ID) compromises the developing hippocampus, driving adult deficits despite iron repletion. The gene expression changes and regulatory mechanisms that drive these lasting deficits are poorly understood. In previous animal studies of ID, concurrent anemia has bee ...
UCD Medicine Research - University College Dublin
... We are entering a period of unprecedented change in Ireland, both in terms of how we provide clinical services, and in the alignment of research and innovation strategies to provide better healthcare and outcomes for the Irish population. It is of paramount importance that UCD and our partners in Ir ...
... We are entering a period of unprecedented change in Ireland, both in terms of how we provide clinical services, and in the alignment of research and innovation strategies to provide better healthcare and outcomes for the Irish population. It is of paramount importance that UCD and our partners in Ir ...
International FOP Association, Inc.
... funding medical research and member programs. The IFOPA’s support for medical research led to the FOP gene discovery in 2006. Our program dollars have funded four (4) International Symposia as well as numerous family gatherings and informational meetings, $40,000+ in LIFE Award scholarships to perso ...
... funding medical research and member programs. The IFOPA’s support for medical research led to the FOP gene discovery in 2006. Our program dollars have funded four (4) International Symposia as well as numerous family gatherings and informational meetings, $40,000+ in LIFE Award scholarships to perso ...